Novel oral plasminogen activator inhibitor-1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats

An orally bioavailable small molecule inhibitor of plasminogen activator inhibitor-1 (PAI-1) is currently being clinically assessed as a novel antithrombotic agent. Although PAI-1 is known to serve a key role in the pathogenesis of metabolic syndrome (MetS) including nonalcoholic steatohepatitis (NA...

Descripción completa

Detalles Bibliográficos
Autores principales: Noguchi, Ryuichi, Kaji, Kosuke, Namisaki, Tadashi, Moriya, Kei, Kawaratani, Hideto, Kitade, Mitsuteru, Takaya, Hiroaki, Aihara, Yosuke, Douhara, Akitoshi, Asada, Kiyoshi, Nishimura, Norihisa, Miyata, Toshio, Yoshiji, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453658/
https://www.ncbi.nlm.nih.gov/pubmed/32945412
http://dx.doi.org/10.3892/mmr.2020.11360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453658/
https://www.ncbi.nlm.nih.gov/pubmed/32945412
http://dx.doi.org/10.3892/mmr.2020.11360

Ejemplares similares